Supernus Pharmaceuticals, Inc. $SUPN Stake Reduced by Vanguard Group Inc.

Vanguard Group Inc. lowered its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,044,750 shares of the specialty pharmaceutical company’s stock after selling 160,506 shares during the quarter. Vanguard Group Inc. owned approximately 0.11% of Supernus Pharmaceuticals worth $288,879,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its holdings in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $50,000. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the period. State of Wyoming acquired a new position in shares of Supernus Pharmaceuticals in the third quarter worth about $68,000. Finally, EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SUPN. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday. Stifel Nicolaus upped their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $62.17.

Insider Activity

In other news, Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. The trade was a 56.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 25,185 shares of company stock valued at $1,268,022. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ SUPN opened at $54.73 on Friday. The company has a 50-day moving average of $50.69 and a two-hundred day moving average of $48.30. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company has a market cap of $3.14 billion, a PE ratio of -80.48, a P/E/G ratio of 1.73 and a beta of 0.71.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.